Cargando…
Monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: Predictions using an integrated Alzheimer’s Disease Platform
For many years, clinical research in Alzheimer’s disease (AD) has focused on attempts to identify the most explicit biomarker, namely amyloid beta. Unfortunately, the numerous therapies that have been developed have failed in clinical practice. AD arises as a consequence of multiple factors, and as...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213414/ https://www.ncbi.nlm.nih.gov/pubmed/33818905 http://dx.doi.org/10.1002/psp4.12628 |
_version_ | 1783709842382258176 |
---|---|
author | Karelina, Tatiana Lerner, Stepan Stepanov, Alexandr Meerson, Mark Demin, Oleg |
author_facet | Karelina, Tatiana Lerner, Stepan Stepanov, Alexandr Meerson, Mark Demin, Oleg |
author_sort | Karelina, Tatiana |
collection | PubMed |
description | For many years, clinical research in Alzheimer’s disease (AD) has focused on attempts to identify the most explicit biomarker, namely amyloid beta. Unfortunately, the numerous therapies that have been developed have failed in clinical practice. AD arises as a consequence of multiple factors, and as such it requires a more mechanistic analytical approach than statistical modeling. Quantitative systems pharmacology modeling is a valuable tool for drug development. It utilizes in vitro data for the calibration of parameters, embeds them into physiologically based structures, and explores translation between animals and humans. Such an approach allows for a quantitative study of the dynamics of the interactions between multiple factors or variables. Here, we present an overview of the quantitative translational model in AD, which embraces current preclinical and clinical data. The previously published description of amyloid physiology has been updated and joined with a model for tau pathology and multiple intraneuronal processes responsible for cellular transport, metabolism, or proteostasis. In addition, several hypotheses regarding the best correlates of cognitive deterioration have been validated using clinical data. Here, the amyloid hypothesis was unable to predict the aducanumab clinical trial data, whereas simulations of cognitive impairment coupled with tau seeding or neuronal breakdown (expressed as caspase activity) matched the data. A satisfactory validation of the data from multiple preclinical and clinical studies was followed by an attempt to predict the results of combinatorial treatment with targeted immunotherapy and activation of autophagy using rapamycin. The combination is predicted to yield better efficacy than immunotherapy alone. |
format | Online Article Text |
id | pubmed-8213414 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82134142021-06-28 Monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: Predictions using an integrated Alzheimer’s Disease Platform Karelina, Tatiana Lerner, Stepan Stepanov, Alexandr Meerson, Mark Demin, Oleg CPT Pharmacometrics Syst Pharmacol Reviews For many years, clinical research in Alzheimer’s disease (AD) has focused on attempts to identify the most explicit biomarker, namely amyloid beta. Unfortunately, the numerous therapies that have been developed have failed in clinical practice. AD arises as a consequence of multiple factors, and as such it requires a more mechanistic analytical approach than statistical modeling. Quantitative systems pharmacology modeling is a valuable tool for drug development. It utilizes in vitro data for the calibration of parameters, embeds them into physiologically based structures, and explores translation between animals and humans. Such an approach allows for a quantitative study of the dynamics of the interactions between multiple factors or variables. Here, we present an overview of the quantitative translational model in AD, which embraces current preclinical and clinical data. The previously published description of amyloid physiology has been updated and joined with a model for tau pathology and multiple intraneuronal processes responsible for cellular transport, metabolism, or proteostasis. In addition, several hypotheses regarding the best correlates of cognitive deterioration have been validated using clinical data. Here, the amyloid hypothesis was unable to predict the aducanumab clinical trial data, whereas simulations of cognitive impairment coupled with tau seeding or neuronal breakdown (expressed as caspase activity) matched the data. A satisfactory validation of the data from multiple preclinical and clinical studies was followed by an attempt to predict the results of combinatorial treatment with targeted immunotherapy and activation of autophagy using rapamycin. The combination is predicted to yield better efficacy than immunotherapy alone. John Wiley and Sons Inc. 2021-05-02 2021-06 /pmc/articles/PMC8213414/ /pubmed/33818905 http://dx.doi.org/10.1002/psp4.12628 Text en © 2021 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Reviews Karelina, Tatiana Lerner, Stepan Stepanov, Alexandr Meerson, Mark Demin, Oleg Monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: Predictions using an integrated Alzheimer’s Disease Platform |
title | Monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: Predictions using an integrated Alzheimer’s Disease Platform |
title_full | Monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: Predictions using an integrated Alzheimer’s Disease Platform |
title_fullStr | Monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: Predictions using an integrated Alzheimer’s Disease Platform |
title_full_unstemmed | Monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: Predictions using an integrated Alzheimer’s Disease Platform |
title_short | Monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: Predictions using an integrated Alzheimer’s Disease Platform |
title_sort | monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: predictions using an integrated alzheimer’s disease platform |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213414/ https://www.ncbi.nlm.nih.gov/pubmed/33818905 http://dx.doi.org/10.1002/psp4.12628 |
work_keys_str_mv | AT karelinatatiana monoclonalantibodytherapyefficacycanbeboostedbycombinationswithothertreatmentspredictionsusinganintegratedalzheimersdiseaseplatform AT lernerstepan monoclonalantibodytherapyefficacycanbeboostedbycombinationswithothertreatmentspredictionsusinganintegratedalzheimersdiseaseplatform AT stepanovalexandr monoclonalantibodytherapyefficacycanbeboostedbycombinationswithothertreatmentspredictionsusinganintegratedalzheimersdiseaseplatform AT meersonmark monoclonalantibodytherapyefficacycanbeboostedbycombinationswithothertreatmentspredictionsusinganintegratedalzheimersdiseaseplatform AT deminoleg monoclonalantibodytherapyefficacycanbeboostedbycombinationswithothertreatmentspredictionsusinganintegratedalzheimersdiseaseplatform |